Literature DB >> 28287646

Developing quality assurance for pediatric autologous stem cell transplants in England: results of a 3-year national audit of activity and engraftment by treatment centre.

D A Morgenstern1,2, P Gray3, A Prudhoe3, M Watts4, K Wheeler5.   

Abstract

Mesh：

Year:  2017        PMID： 28287646     DOI： 10.1038/bmt.2017.32

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  8 in total

1.  The UK Experience of a Treatment Strategy for Pediatric Metastatic Medulloblastoma Comprising Intensive Induction Chemotherapy, Hyperfractionated Accelerated Radiotherapy and Response Directed High Dose Myeloablative Chemotherapy or Maintenance Chemotherapy (Milan Strategy).

Authors:  Sindu Vivekanandan; Richard Breene; Ramya Ramanujachar; Heidi Traunecker; Barry Pizer; Mark N Gaze; Frank Saran; Nicky Thorp; Martin English; Kate Ah Wheeler; Antony Michalski; David A Walker; Daniel Saunders; Fiona Cowie; Alison Cameron; Susan V Picton; Deepak Parashar; Gail Horan; Michael V Williams
Journal:  Pediatr Blood Cancer       Date:  2015-08-14       Impact factor: 3.167

Review 2.  JACIE accreditation in paediatric haemopoietic SCT.

Authors:  J M Cornish
Journal:  Bone Marrow Transplant       Date:  2008-10       Impact factor: 5.483

Review 3.  Optimisation and quality control of cell processing for autologous stem cell transplantation.

Authors:  Michael J Watts; David C Linch
Journal:  Br J Haematol       Date:  2016-10-17       Impact factor: 6.998

4.  Honest reporting and elucidation of very serious adverse events: a lesson to us all.

Authors:  Peter Hokland; Finbarr Cotter
Journal:  Br J Haematol       Date:  2016-06-24       Impact factor: 6.998

5.  Post-thaw viability of cryopreserved peripheral blood stem cells (PBSC) does not guarantee functional activity: important implications for quality assurance of stem cell transplant programmes.

Authors:  Daniel A Morgenstern; Gulrukh Ahsan; Margaret Brocklesby; Stuart Ings; Carmen Balsa; Paul Veys; Penelope Brock; John Anderson; Persis Amrolia; Nicholas Goulden; Catherine M Cale; Michael J Watts
Journal:  Br J Haematol       Date:  2016-06-12       Impact factor: 6.998

6.  Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study.

Authors:  Katherine K Matthay; C Patrick Reynolds; Robert C Seeger; Hiroyuki Shimada; E Stanton Adkins; Daphne Haas-Kogan; Robert B Gerbing; Wendy B London; Judith G Villablanca
Journal:  J Clin Oncol       Date:  2009-01-26       Impact factor: 44.544

7.  Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma.

Authors:  Lorenza Gandola; Maura Massimino; Graziella Cefalo; Carlo Solero; Filippo Spreafico; Emilia Pecori; Daria Riva; Paola Collini; Emanuele Pignoli; Felice Giangaspero; Roberto Luksch; Serena Berretta; Geraldina Poggi; Veronica Biassoni; Andrea Ferrari; Bianca Pollo; Claudio Favre; Iacopo Sardi; Monica Terenziani; Franca Fossati-Bellani
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

8.  28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures.

Authors:  R Ladenstein; U Pötschger; O Hartman; A D J Pearson; T Klingebiel; V Castel; I Yaniv; T Demirer; G Dini
Journal:  Bone Marrow Transplant       Date:  2008-06       Impact factor: 5.483
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.